Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Overview of attention for article published in New England Journal of Medicine, January 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 27 news outlets
blogs: 1 blog
policy: 3 policy sources
twitter: 122 X users
patent: 22 patents

facebook: 3 Facebook pages
wikipedia: 1 Wikipedia page
video: 1 YouTube creator
guideline: 4 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 483 Mendeley

So far, Altmetric has seen 149 X posts from 122 X users, with an upper bound of 1,722,615 followers.

RT @SeeFisch: Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes | NEJM https://t.co/KcMgDUeFUq

10) In #MEDALIST (🔓https://t.co/JMH5XtjY8x), @FenauxP et al showed that #luspatercept ⬇️severity of anemia in pts w/LR-#MDS-RS who had been receiving regular transfusions & were refractory to or unlikely to respond to #ESA. https://t.co/3kutMQlIth

8c) #Luspatercept is a recombinant fusion protein that binds select transforming growth factor β superfamily ligands to decrease SMAD2 & SMAD3 signaling, thereby enabling erythroid maturation, especially late-stage erythroblast differentiation. See 🔓…

7. #Luspatercept for transfusion-dependent lower-risk MDS with ring sideroblasts! (8/12) https://t.co/YOG5nYy6km https://t.co/lg6jRzvF4G

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 145 additional X posts.